Abstract 1152P
Background
Somatostatin-receptor (SSTR)-targeted-PET/CT is widely used for diagnosis and disease monitoring of pheochromocytoma / paraganglioma (PPGLs). The aim of this study was to assess the potential of the novel SSTR-targeted tracer [18F]-SiTATE in diagnosing PPGLs by comparing imaging parameters to tumor marker levels and secretory activity in a small cohort of patients diagnosed with this rare tumor type.
Methods
All patients with histologically confirmed PPGL presenting for [18F]-SiTATE-PET/CT at LMU Klinikum between 10/2020 and 02/2024 as well as hormonal laboratory analysis of both plasma and 24-hour urine samples within up to 100 days were included. Metabolic tumor volume (MTV) was assessed using a threshold of mean standard uptake value (SUVmean) of 5.0. Total lesion uptake (TLU) was assessed with SUVmean x MTV. Correlation was tested using spearmanś rank correlation test.
Results
34/39 patients (median age: 55, range: 5-83) were included in this study. 5 patients with cervical PGL were excluded. 21 patients had metastatic disease. There was a moderate correlation between TLU and MTV and urinary dopamine (r=0.50-0.51, p<0.05) as well as norepinephrine (r=0.50-0.54, p<0.05). TLU and MTV correlated moderately with serum chromogranin-A levels (r= 0.60, p<0.01, respectively). A moderate correlation was determined between TLU and MTV with plasma normetaphrine and 3-Methoxytyramine (r=0.52-0.56, p<0.01).
Conclusions
MTV and TLU measured with [18F]-SiTATE-PET/CT correlate well with the tumor marker chromogranin-A in serum and with particular biomarkers of the catecholamine pathway in urine and plasma, reflecting metabolic tumor activity. Within the limits imposed by the relatively small cohort, our results suggest that TLU in [18F]-SiTATE-PET/CT could be used as imaging biomarker for monitoring of disease progression and secretory activity in patients with PPGL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1156P - The efficacy of lower doses of everolimus in patients with advanced neuroendocrine tumors
Presenter: Rachel Riechelmann
Session: Poster session 17
1157P - Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry
Presenter: Jorge Hernando Cubero
Session: Poster session 17
1158P - A novel nomogram for predicting overall survival of small intestinal neuroendocrine tumors treated with PRRT
Presenter: Dimitrios Papantoniou
Session: Poster session 17
1159P - Molecular characterization of extra-pulmonary mixed adeno-neuroendocrine carcinomas: The NIRVANA substudy
Presenter: Francesca Spada
Session: Poster session 17
1160P - An Italian multicenter phase II trial of metronomic temozolomide in unfit patients with advanced neuroendocrine neoplasms: Interim analysis of the MeTe study
Presenter: Francesca Spada
Session: Poster session 17
1161P - Progression-free survival ratio and the implications for treatment sequencing in neuroendocrine neoplasms
Presenter: Philipp Melhorn
Session: Poster session 17
1162P - Transcriptomic analysis of gastroenteropancreatic neuroendocrine tumours with carcinoid syndrome
Presenter: Javier Pozas Perez
Session: Poster session 17
1163P - Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
Presenter: Eduardo Terán Brage
Session: Poster session 17
1164P - The influence of neoadjuvant radiotherapy on surgical management and prognostic outcomes in locally advanced rectal neuroendocrine carcinoma
Presenter: Weiran Xu
Session: Poster session 17